LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation

Nat Immunol. 2022 May;23(5):757-767. doi: 10.1038/s41590-022-01176-4. Epub 2022 Apr 18.

Abstract

LAG3 is an inhibitory receptor that is highly expressed on exhausted T cells. Although LAG3-targeting immunotherapeutics are currently in clinical trials, how LAG3 inhibits T cell function remains unclear. Here, we show that LAG3 moved to the immunological synapse and associated with the T cell receptor (TCR)-CD3 complex in CD4+ and CD8+ T cells, in the absence of binding to major histocompatibility complex class II-its canonical ligand. Mechanistically, a phylogenetically conserved, acidic, tandem glutamic acid-proline repeat in the LAG3 cytoplasmic tail lowered the pH at the immune synapse and caused dissociation of the tyrosine kinase Lck from the CD4 or CD8 co-receptor, which resulted in a loss of co-receptor-TCR signaling and limited T cell activation. These observations indicated that LAG3 functioned as a signal disruptor in a major histocompatibility complex class II-independent manner, and provide insight into the mechanism of action of LAG3-targeting immunotherapies.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, CD / immunology
  • CD3 Complex / immunology
  • CD8 Antigens / metabolism
  • CD8-Positive T-Lymphocytes*
  • Histocompatibility Antigens Class II
  • Lymphocyte Activation Gene 3 Protein
  • Lymphocyte Specific Protein Tyrosine Kinase p56(lck)* / metabolism
  • Receptors, Antigen, T-Cell / metabolism
  • Signal Transduction

Substances

  • Antigens, CD
  • CD3 Complex
  • CD8 Antigens
  • Histocompatibility Antigens Class II
  • Receptors, Antigen, T-Cell
  • Lymphocyte Specific Protein Tyrosine Kinase p56(lck)
  • Lymphocyte Activation Gene 3 Protein